Search

Researchers wanted to develop skin liposomal formulations that would carry 5-fluorouracil to the cancer site in an adjuvant way, as well as enhancing the health of basal cell carcinoma patients who were experiencing unfavorable consequences. Using Strat-M films in vitro, the detailed skin-damaging potential of the synthesized skin liposomes and the sensitivity to 5-fluorouracil were evaluated. It was found that the Korsmeyer-Pepas condition was the best one for controlling drug administration. Additionally, it is unknown if it might irritate skin. The vitality and hemolytic potential of the cytostatic effect on the recommended anti-tumor therapy were also examined in in vitro investigations. Our findings suggest that a sodium alginate and hyaluronic acid crosslinked gel containing AS1411 aptamer liposomes coated with 5-fluorouracil is the optimal liposome solution. This liposome characterization appears to have good biological safety implications and may be exploited as a different approach to basal cell carcinoma skin treatments. [ABSTRACT FROM AUTHOR]

The limited water solubility and dissolution of drugs classified under the Biopharmaceutics Classification System (BCS) class II category provide constraints on their oral bioavailability. In the present study, a self-micro emulsifying drug delivery system (SMEDDS) was employed to enhance the aqueous solubility and oral bioavailability of toremifene, which belongs to the Biopharmaceutics Classification System (BCS) class II category. The selection of Oleic Acid, Transcutol-P, and Span 20 as the oil, surfactant combination, and cosurfactant, respectively, was based on the solubility. The optimal composition (Oleic Acid / Transcutol-P / Span 20 in a volume ratio) for toremifene, which exhibits a small droplet size (132.1 nm) and consistent microemulsification was determined by the use of pseudo-ternary phase diagrams. Differential scanning calorimetry and powder X-ray diffraction were employed to identify the loss of crystallinity in lyophilized toremifene. The results indicated that toremifene existed in a molecularly dissolved or amorphous state inside the SMEDDS formulation. The saturation solubility and dissolving rate of toremifene -SMEDDS exhibited significant enhancements compared to toremifene powder when tested in water, simulated gastric fluid (pH 1.2), and simulated intestinal fluid (pH 6.8). The female rats exhibited a 1.94-fold increase in the area under the curve and a 1.80-fold increase in the highest plasma concentration following the oral administration of toremifene-SMEDDS compared to the oral administration of the toremifene dispersion. In summary, the findings of our study suggest that self-microemulsifying drug delivery systems (SMEDDS) have promise as an oral formulation for enhancing the therapeutic efficacy of toremifene. [ABSTRACT FROM AUTHOR]